Skip to content

Study · Non-randomized trial · n = 31 · 2010

2 results

The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.

Anastasilakis AD, Polyzos SA, Avramidis A, Toulis KA, Papatheodorou A, Terpos E

Clinical endocrinology15 Oct 2009Cited by 42 (Europe PMC)

PMID19832854 (opens in a new tab)DOI10.1111/j.1365-2265.2009.03728.x (opens in a new tab)PepBankPUB-19832854
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialMechanism

    In postmenopausal women with osteoporosis, serum Dkk-1 increased significantly during teriparatide treatment versus baseline.

    In plain wordsIn women with osteoporosis, teriparatide increased serum Dkk-1 compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum Dkk-1 during treatment
    Study

    n = 31

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · injection · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Dkk-1 increased significantly during TPTD administration (P < 0.044) and decreased to baseline 6 months after TPTD discontinuation.
    1 context sentence
    Summary · context
    A total of 31 postmenopausal Caucasian women with established osteoporosis (mean age 66.3 +/- 1.4 years) received daily injections of 20 microg TPTD for 18 months.
  2. 02HumanNon-randomized trialMechanism

    In women with osteoporosis, serum Dkk-1 decreased to baseline six months after teriparatide discontinuation.

    In plain wordsIn women with osteoporosis, serum Dkk-1 returned to baseline after teriparatide stopped.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseSerum Dkk-1 after discontinuation
    Study

    n = 31

    Comparator
    During teriparatide administration
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · injection · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Dkk-1 increased significantly during TPTD administration (P < 0.044) and decreased to baseline 6 months after TPTD discontinuation.
    1 context sentence
    Summary · context
    A total of 31 postmenopausal Caucasian women with established osteoporosis (mean age 66.3 +/- 1.4 years) received daily injections of 20 microg TPTD for 18 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.